8-K: Insmed's Once-Daily TPIP Achieves Positive Phase 2b Results in Pulmonary Arterial Hypertension, Paving Way for Phase 3 Trials

Insmed Incorporated announced highly positive topline results from its Phase 2b study of treprostinil palmitil inhalation powder (TPIP) for pulmonary arterial hypertension (PAH), meeting all primary and secondary efficacy endpoints and demonstrating sustained benefit with once-daily dosing.

Summary

• Insmed's Phase 2b study of treprostinil palmitil inhalation powder (TPIP) in patients with pulmonary arterial hypertension (PAH) met its primary endpoint and all secondary efficacy endpoints.
• The primary endpoint showed a statistically significant 35% placebo-adjusted reduction from baseline in pulmonary vascular resistance (PVR), with a Least Squares (LS) mean ratio of 0.65 (95% Confidence Interval (CI): 0.54, 0.79; p<0.001).
• Secondary efficacy endpoints included a 35.5-meter placebo-adjusted improvement in six-minute walk distance (6MWD) (95% CI: 11.2, 60.7; p=0.003) and a 60% placebo-adjusted reduction from baseline in N-terminal pro b-type natriuretic peptide (NT-proBNP) concentrations (LS mean ratio of 0.40; 95% CI: 0.27, 0.59; p<0.001).
• Efficacy was evaluated approximately 24 hours after therapy administration, demonstrating sustained therapeutic effect with once-daily dosing.
• TPIP was generally well-tolerated in the study; 75% of patients treated with TPIP titrated to the maximum allowed dose of 640 µg once daily.
• The study involved 102 patients (69 TPIP, 33 placebo) randomized 2:1 for 16 weeks across 44 global sites.
• Overall, 90% of patients receiving TPIP and all patients receiving placebo completed the study.
• Insmed plans to engage with the U.S. Food and Drug Administration (FDA) regarding the Phase 3 trial design for PAH.
• The company intends to initiate a Phase 3 trial in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD) before the end of 2025 and a Phase 3 trial in patients with PAH in early 2026.
• 95% of patients who completed the Phase 2b study enrolled in the long-term open-label extension, which will evaluate TPIP up to a maximum allowable dose of 1,280 µg once daily.

Sentiment

Score: 9

Explanation: The document reports highly positive and statistically significant topline results from a Phase 2b clinical trial for a drug targeting a serious, rare disease. The drug met all primary and secondary endpoints, demonstrated sustained efficacy with once-daily dosing, and was generally well-tolerated. This significantly de-risks the program and sets the stage for Phase 3 trials, indicating strong potential for future regulatory approval and market success. The only minor negatives are the higher incidence of TEAEs compared to placebo, but these are consistent with known profiles and did not lead to high discontinuation rates.

Positives

• The Phase 2b study of TPIP in PAH met its primary endpoint with a highly statistically significant 35% placebo-adjusted reduction in pulmonary vascular resistance (PVR) (p<0.001).
• All secondary efficacy endpoints were met, including a clinically meaningful 35.5-meter placebo-adjusted improvement in six-minute walk distance (6MWD) (p=0.003) and a significant 60% placebo-adjusted reduction in NT-proBNP concentrations (p<0.001).
• The efficacy of TPIP was demonstrated approximately 24 hours after administration, confirming its sustained benefit as a once-daily therapy.
• TPIP was generally well-tolerated in the study, with 75% of patients successfully titrating to the maximum allowed dose of 640 µg once daily.
• A high proportion of patients (90% of TPIP group, 100% of placebo group) completed the 16-week study, indicating good tolerability and patient retention.
• No deaths occurred in the study, and serious adverse events were relatively low (7.2% for TPIP vs. 3.0% for placebo).
• 95% of patients who completed the Phase 2b study opted to enroll in the long-term open-label extension, suggesting strong patient and clinician confidence in the drug.
• Exploratory endpoints showed more patients on TPIP achieved an improvement in WHO Functional Class (30.4% vs. 15.2% for placebo) and a 15% increase in Cardiac Index compared to placebo (p=0.006).

Negatives

• Treatment-emergent adverse events (TEAEs) occurred more frequently in the TPIP group (88.4%) compared to the placebo group (75.8%).
• Serious TEAEs were observed in 7.2% of patients receiving TPIP versus 3.0% of patients receiving placebo.
• Severe TEAEs were observed in 5.8% of patients receiving TPIP versus 3.0% of patients receiving placebo.
• TEAEs leading to treatment discontinuation were experienced by 5.8% of patients taking TPIP, whereas none occurred in the placebo arm.
• The most common TEAEs occurring more frequently with TPIP than with placebo included cough (40.6% vs. 21.2%), headache (31.9% vs. 15.2%), fatigue (10.1% vs. 3.0%), chest discomfort (8.7% vs. 0.0%), flushing (8.7% vs. 3.0%), upper respiratory tract infection (7.2% vs. 3.0%), and non-cardiac chest pain (5.8% vs. 3.0%).

Risks

• The full data set from the TPIP PAH study or data generated in further clinical trials of TPIP may not be consistent with the topline results.
• Failure to successfully conduct future clinical trials for TPIP, including the planned Phase 3 program, due to potential inability to enroll or retain sufficient patients or generate data necessary for regulatory approval.
• Development of unexpected safety or efficacy concerns related to TPIP during further development.
• Failure of third parties, on whom the Company is dependent, to manufacture sufficient quantities of TPIP for clinical needs, to conduct clinical trials, or to comply with agreements or regulations.
• Failure to obtain regulatory approval for TPIP from authorities like the FDA.
• Inaccuracies in the Company's estimates of the size of the potential markets for TPIP or in data used to identify physicians.
• Expected rates of patient uptake, duration of expected treatment, or expected patient adherence or discontinuation rates may not be achieved if TPIP is approved.
• Inability of the Company or its third-party manufacturers to comply with regulatory requirements related to TPIP.
• Inability to obtain adequate reimbursement from government or third-party payors for TPIP or acceptable prices for TPIP, if approved.
• Restrictions or other obligations imposed by agreements related to TPIP and failure to comply with such obligations.
• Clinical studies may be delayed, or serious side effects may be identified during drug development.
• Challenges regarding the strength and enforceability of the Company's intellectual property rights or the rights of third parties.
• The cost and potential reputational damage resulting from litigation to which the Company may become a party, including product liability claims.

Future Outlook

Insmed plans to immediately engage with the U.S. Food and Drug Administration (FDA) to discuss the Phase 3 trial design for TPIP in PAH. The company intends to initiate a Phase 3 trial for pulmonary hypertension associated with interstitial lung disease (PH-ILD) before the end of 2025 and a Phase 3 trial for PAH in early 2026. The long-term open-label extension study for TPIP will continue to evaluate the drug up to a maximum allowable dose of 1,280 µg once daily. Detailed results from the Phase 2b study and the open-label extension will be presented at future medical meetings.

Management Comments

• "The statistically significant and clinically meaningful results shown with TPIP in pulmonary arterial hypertension mark a potential breakthrough for patients and the future of prostanoid therapy." Gene Sullivan, M.D., Chief Product Strategy Officer of Insmed.
• "TPIP was designed with the goal of fully harnessing the potential of treprostinil and providing meaningful benefit to patients. These unprecedented Phase 2b results unequivocally demonstrate TPIPs potential to be a highly effective and well-tolerated once-daily prostanoid therapy for the treatment of PAH across disease severities and background treatment regimens." Gene Sullivan, M.D., Chief Product Strategy Officer of Insmed.
• "Todays outstanding results for TPIP represent more than a decade of hard work and the application of innovative chemistry intended to deliver a safe and effective, once-daily inhaled prostanoid therapy for patients with PAH, a devastating, progressive disease." Martina Flammer, M.D., MBA, Chief Medical Officer of Insmed.
• "Having met the primary endpoint with high statistical significance, as well as seeing positive results for all secondary efficacy endpoints, we are excited about TPIPs potential to become the prostanoid of choice." Martina Flammer, M.D., MBA, Chief Medical Officer of Insmed.

Industry Context

Pulmonary arterial hypertension (PAH) is a severe, progressive, and rare disease affecting an estimated 35,000 patients in the U.S., 40,000 in EU5, and 15,000 in Japan. Current inhaled treprostinil therapies often require frequent dosing (e.g., four times daily), which can significantly impact patient adherence and quality of life. Insmed's TPIP, designed as a once-daily inhaled therapy, aims to address this unmet need by offering sustained therapeutic effect and improved convenience. The positive Phase 2b results position TPIP as a potential 'prostanoid of choice,' suggesting a significant advancement in the treatment landscape for PAH and potentially for pulmonary hypertension associated with interstitial lung disease (PH-ILD), where topline Phase 2a results were previously reported.

Comparison to Industry Standards

• TPIP is designed as a once-daily inhaled therapy, offering a significant advantage over conventional inhaled treprostinils that typically require four-times-daily dosing, potentially improving patient adherence and convenience.
• The sustained therapeutic effect of TPIP, demonstrated by efficacy being evaluated approximately 24 hours after administration, suggests a competitive profile in terms of drug durability compared to existing therapies.
• TPIP's inert formula aims to limit adverse airway effects and minimize systemic exposure, addressing challenges associated with rapid systemic metabolism and systemic/local adverse effects seen with some conventional prostanoids.
• The company's stated goal for TPIP to become the 'prostanoid of choice' implies a competitive edge in efficacy, safety, and patient experience over current market options for PAH.

Stakeholder Impact

• Shareholders: Highly positive news, likely to increase investor confidence and potentially share price due to significant progress in a key pipeline asset and de-risking of future development.
• Patients (PAH & PH-ILD): Offers hope for a new, potentially more effective and convenient once-daily treatment option for a debilitating and often fatal disease, improving quality of life and clinical outcomes.
• Employees: Positive morale boost and validation of research and development efforts.
• Healthcare Providers: Provides a promising new therapeutic option to consider for their PAH patients, especially given the once-daily dosing convenience.
• Regulatory Authorities (FDA): Will be engaged for Phase 3 trial design, indicating significant progress towards potential market approval.

Next Steps

• Engage immediately with the U.S. Food and Drug Administration (FDA) regarding the Phase 3 trial design for TPIP in PAH.
• Initiate a Phase 3 trial in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD) before the end of 2025.
• Initiate a Phase 3 trial in patients with PAH in early 2026.
• Present detailed results from the Phase 2b study of TPIP in PAH and the open-label extension at future medical meetings.
• Continue the long-term open-label extension study, evaluating TPIP up to a maximum allowable dose of 1,280 µg once daily.

Key Dates

Recommendation

Keywords

Pulmonary Arterial Hypertension, PAH, Treprostinil Palmitil Inhalation Powder, TPIP, Clinical Trial, Phase 2b, Biopharmaceutical, Drug Development, FDA, Orphan Drug, Rare Disease, Pulmonary Hypertension Interstitial Lung Disease, PH-ILD